Pfizer has quietly built momentum in 2026 and Guggenheim just raised its price target to $36 while reiterating a Buy rating.
Is PFE a good stock to buy now? We came across a bullish thesis on Pfizer Inc. on Investomine’s Substack. In this article, we ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results